Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (PIRS) on July 31, 2019. The filing documents events occurring at the Company's Annual Meeting of Stockholders held on the same date. The registrant is incorporated in Nevada and trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial statement line items.
Material Changes and Corporate Actions
- Equity Incentive Plan Approval: Stockholders approved the 2019 Employee, Director and Consultant Equity Incentive Plan (2019 EIP), which was previously adopted by the Board on April 30, 2019. The plan became effective immediately upon stockholder approval.
- Election of Directors: James Geraghty and Ann Barbier, M.D., Ph.D. were elected as Class II directors to serve three-year terms expiring at the 2022 annual meeting.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Voting Participation: A quorum of 36,700,600 shares (74.50% of outstanding shares) was present in person or by proxy out of 49,259,017 eligible shares.
Voting Results Summary
| Matter | Votes For | Votes Against/Withheld | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of James Geraghty | 16,237,602 | 7,860,421 (Withheld) | N/A | 12,602,577 |
| Election of Ann Barbier | 17,207,431 | 6,890,592 (Withheld) | N/A | 12,602,577 |
| 2019 EIP Approval | 22,788,576 | 1,255,448 | 53,999 | 12,602,577 |
| Auditor Ratification | 35,953,793 | 708,004 | 38,803 | 0 |
Guidance, Outlook, and Risks
This filing does not contain management guidance, financial outlook, risk factors, or discussion of contingencies. It strictly reports the results of the Annual Meeting and the adoption of the 2019 EIP.
Key Facts for Investor Verification
- Verify the specific terms of the 2019 Employee, Director and Consultant Equity Incentive Plan by reviewing Exhibit 10.1 attached to this filing or the definitive proxy statement filed on June 18, 2019.
- Confirm the tenure of the newly elected directors, James Geraghty and Ann Barbier, which extends through the 2022 annual meeting.
- Note the significant number of broker non-votes (12,602,577) on the director elections and equity plan approval, indicating shares held by brokers that were not voted on these matters.
- Review the Company's most recent 10-Q or 10-K for actual financial performance data, as this 8-K contains none.